#United States #Lincoln, Nebraska #Neogen® #BCHF #Genomic Test

Introduction to Igenity® BCHF

In a significant move to enhance cattle health, Neogen® Corporation has unveiled Igenity® BCHF, an innovative genomic test specifically designed to address the growing concerns surrounding Bovine Congestive Heart Failure (BCHF). With the potential to revolutionize cattle management practices, this new test could be a game-changer for producers eager to ensure the health and productivity of their herds.

The Challenge of Bovine Congestive Heart Failure

BCHF is a critical issue plaguing the cattle industry, affecting everything from young calves to mature cattle. The condition not only threatens animal health but has broader implications for overall productivity and economic stability in cattle farming. As the industry grapples with this serious concern, Neogen® aims to provide farmers and producers with substantial tools to mitigate these risks through scientific advancements.

Understanding Igenity® BCHF

Igenity® BCHF is a ground-breaking genomic test that evaluates an animal's genetic predisposition to heart failure, offering clear insights through a risk score ranging from 1 (low risk) to 10 (high risk). Research indicates that for each point decrease in an animal's score, there is about a 3.5% reduction in the expected incidence rate of BCHF. By identifying animals with a lower genetic risk, producers can make informed decisions regarding their breeding and management practices.

Victor Pedrosa, Ph.D., Director of Technical Genomics and Innovation at Neogen, emphasizes that the test results directly reflect the risk associated with BCHF, which can be inherited by offspring. This scientific approach equips breeders with the knowledge needed to enhance herd health and diminish the likelihood of disease transmission across generations.

Benefits for the Cattle Industry

The introduction of Igenity® BCHF presents cattle producers with exceptional opportunities. By using this genomic testing method, farms can better manage the risk of BCHF in their herds, ultimately leading to healthier animals and improved economic outcomes. The chance to produce feeder calves with a minimized mortality rate from BCHF creates a pathway for increased profitability and stability in cattle operations.

Kirk Ramsey, DVM, Professional Services Veterinarian with Neogen, highlights the test's capability of quantifying BCHF risk, enabling breeders to make strides towards healthier cattle populations. He notes, "Igenity BCHF is the first genomic test of its kind, providing critical insights into the factors contributing to congestive heart failure in both calves and mature cattle."

Looking Ahead

As BCHF continues to threaten herd viability, innovations like Igenity® BCHF are essential for fostering a more sustainable and productive cattle industry. Neogen®'s commitment to food security solutions makes it a pioneer in pushing forward the boundaries of cattle health management.

For more detailed information about how Igenity® BCHF can benefit your operations, please visit neogen.com/igenity-beef or reach out to a Neogen representative directly.

Conclusion

The launch of Igenity® BCHF marks a new chapter in genomic testing for the cattle industry. By embracing advanced testing techniques and putting science to work, producers can take valuable steps toward enhancing animal health and ensuring the prosperity of their businesses. This innovative solution not only addresses immediate health concerns but also sets a precedent for future advancements in livestock management.

Neogen's initiatives in this space are commendable, and as the industry evolves, such innovations will play a pivotal role in safeguarding the wellbeing of livestock and the integrity of the agricultural sector as a whole.